Furthermore, exploration of the molecular mechanisms underlying NR4A2-associated intellectual developmental disorder with language impairment and early-onset DOPA-responsive dystonia-parkinsonism is imperative for the development of efficacious therapies and enhanced clinical outcomes. This evidence concerns the gene NR4A2 and Parkinson disease.